In ovarian cancer cells, we showed that knockdown of BCL2 also reduces CSC-like populations, suggesting that the LARP1-mediated anti-CSC phenotype may also be mediated via BCL2 expression. This evidence concerns the gene BCL2 and ovarian cancer.